Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications

Articolo

Data di Pubblicazione:

2024

Citazione:

Addante, F., D'Amati, A., Santoro, A., Angelico, G., Inzani, F., Arciuolo, D., Travaglino, A., Raffone, A., D'Alessandris, N., Scaglione, G., Valente, M., Tinnirello, G., Sfregola, S., Padial Urtueta, B., Piermattei, A., Cianfrini, F., Mulè, A., Bragantini, E., Zannoni, G. F., Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications, <>, 2024; 25 (2): 1056-1062. [doi:10.3390/ijms25021056] [https://hdl.handle.net/10807/271422]

Abstract:

Among the four endometrial cancer (EC) TCGA molecular groups, the MSI/hypermutated group represents an important percentage of tumors (30%), including different histotypes, and generally confers an intermediate prognosis for affected women, also providing new immunotherapeutic strategies. Immunohistochemistry for MMR proteins (MLH1, MSH2, MSH6 and PMS2) has become the optimal diagnostic MSI surrogate worldwide. This review aims to provide state-of-the-art knowledge on MMR deficiency/MSI in EC and to clarify the pathological assessment, interpretation pitfalls and reporting of MMR status.

Tipologia CRIS:

Articolo in rivista, Nota a sentenza

Keywords:

ENDOMETRIAL CANCER

Elenco autori: